

IN THE SPECIFICATION

At page 1, before the heading "DESCRIPTION", please insert the following new paragraph:

[0000] This application is a U.S. national stage filing under 35 U.S.C. §371 of International Application No. PCT/EP2004/008168 filed on July 22, 2004, which claims priority of German Application No. DE 103 34 188.9 filed on July 26, 2003. This application contains subject matter that is related to a concurrently filed U.S. Application by the same applicants titled "Substituted 2-aminotetralin for the treatment of depression" (Serial No. not yet assigned). The disclosure of each of the applications identified in this paragraph is incorporated herein by reference in its entirety.

Please replace paragraph [0010] with the following replacement paragraph:

[0010] In a further animal model (Embodiment 3) an investigation was made as to whether the antidepressive effects of rotigotine can be distinguished from a general motor stimulation. In this case, rotigotine was administered to rats, whose olfactory bulb had been removed on both sides. The removal of the olfactory bulb leads in the untreated control group to an adaptive hyperactivity. It is known from the literature that chronically administered antidepressants lead to a reduction in movement activity of the animals in this model, while stimulants further increase the motor activity (van Riezen H *et al.*, Br. J. Pharmacol. 60(4), 1977, 521; Kelly JP *et al.*, Pharmacol. Ther. 74(3), 1997, 299). Therefore, it is possible to discriminate between antidepressive and non-specific stimulatory effects of an active ingredient with this model. It has now been shown that rotigotine exhibits a specifically antidepressive effect in low doses that approximately corresponds to the effect of the antidepressant imipramine and which leads to virtually complete suppression of the bulbectomy-induced locomotor hyperactivity. In higher rotigotine concentrations, on the other hand, the stimulatory dopamine-agonistic effect predominates.

Please replace paragraph [0016] with the following replacement paragraph:

[0016] A subject of the invention is therefore the use of rotigotine, its prodrugs and salts for producing a pharmaceutical agent for treating depression, and a method for treating depression in a mammal, comprising administering to the mammal a therapeutically effective amount of rotigotine, or a prodrug thereof, or a physiologically

acceptable salt thereof. The term “treating” in this patent application comprises both the treatment of existing depression and the preventative treatment (prophylaxis) of depression, for example of recurring depressive phases.

Please replace paragraphs [0020] and [0021] with the following replacement paragraphs:

[0020] Rotigotine and its prodrugs and salts are basically suitable for ~~the production of a medication~~ administering to a mammal for treating the various, above-mentioned forms of depression or for treating affective disorders, in particular depressive episodes, recurring depressive disorders and depressive phases in bipolar affective disorders, according to ICD-10.

[0021] According to the invention, rotigotine is preferably used for ~~producing a medication for~~ treating depressive episodes and serious recurring depressive disorders such as occur, for example in endogenous, unipolar depression (“major depression”).

Please replace paragraph [0024] with the following replacement paragraph:

[0024] Rotigotine CC(C)[C@H](NC1=CC=C(C=C1)CC2=CC=CC=C2)C3=CC=CC=C3 and its prodrugs and salts are also especially suitable for ~~producing antidepressants for~~ treating depressive episodes in manic-depressive patients.

Please replace paragraph [0026] with the following replacement paragraph:

[0026] Rotigotine is also preferably used for ~~producing a pharmaceutical agent for~~ treating “organic” depression, as described above. Organic depression occurs frequently, for example, in Parkinson’s disease[[s]], or in cerebrovascular diseases and in dementia disorders.

Please replace paragraphs [0028] and [0029] with the following replacement paragraphs:

[0028] A subject of the invention is therefore the use of rotigotine, its metabolites, prodrugs and salts, for producing a pharmaceutical agent for the treatment of depression associated with Parkinson’s disease; and a method for treating depression associated with Parkinson’s disease in a mammal, comprising administering to the mammal a therapeutically effective amount of rotigotine, or a metabolite, a prodrug or a physiologically acceptable salt thereof, it being possible optionally to dispense with [[a]]

co-medication with other antidepressants.

[0029] Another subject of the invention is the use of rotigotine, its metabolites, prodrugs and salts, in each case alone or in combination with other antidepressants, for treating organic depression, which is not associated with Parkinson's disease; and a method for treating organic depression not associated with Parkinson's disease in a mammal, comprising administering to the mammal a therapeutically effective amount of rotigotine, or a metabolite, prodrug or salt thereof, alone or in combination with another antidepressant. Examples of such organic depression [[is]] are depression in conjunction with brain tumours, migraines, epilepsy, brain paralysis, brain arteriosclerosis, brain traumas, meningitis, stroke, dementia, Alzheimer's disease or the Parkinson Plus Syndrome.